Prevalence and denial of sexual abuse in a male psychiatric inpatient population

While the link between sexual abuse and psychiatric morbidity is well established, there are only a few studies that have investigated the prevalence of sexual abuse in male psychiatric populations and these studies have typically employed designs that ignore methodological issues specific to male sexual abuse. The present study aims to contribute to this research using as methodologically sound approach as possible. Seventy-four male inpatients were interviewed using a questionnaire (J. N. Briere, 1992) about childhood sexual experiences. Approximately one third reported incidents that met this study's criteria for sexual abuse. Many of these men did not label such experiences as "sexual abuse." The results suggest that mental health professionals need to be aware that many of their male patients may have a history of sexual abuse and that potential minimization or denial of it is a barrier to disclosure.     

A new solvothermal method for the synthesis of size-controlled YAG:Ce single-nanocrystals

Ce³⁺-doped Y₃Al₅O₁₂ (YAG:Ce) nanocrystals were synthesized by a unique solvothermal method, under sub-critical conditions. A home-made autoclave was used, operating in a larger pressure and temperature range than that with conventional commercial equipment and allowing direct in situ photoluminescence (PL) and X-ray absorption characterizations. The study of various synthesis conditions (pressure, temperature, precursor concentration, reaction time) allowed the best reaction conditions to be pinpointed to control YAG:Ce nanocrystal size, as well as crystal quality, and to get efficient optical properties. Without any post thermal treatment, we succeeded in obtaining well-crystallized YAG:Ce nanocrystals (30–200 nm), displaying typical PL properties of YAG:Ce with a maximal emission at 550 nm. The pristine 100 nm-sized YAG:Ce nanoparticles present an internal quantum yield of about 40 ± 5%. In situ X-ray absorption near edge spectroscopy demonstrates the presence of Ce⁴⁺ in nanocrystals elaborated at high temperature, resulting from the oxidation of Ce³⁺ during the crystallization process.

This modified solvothermal method, combined with in situ photoluminescence measurements, allows the synthesis of well-crystallized size-controlled YAG:Ce nanocrystals.     

Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials)

Journal of Autism and Developmental Disorders - The author of the article would like to add a video abstract as a supplementary material for a published article. The supplementary file is published...     

Croyances dysfonctionnelles liées au craving : évolution auprès des patients en post-cure d’alcoologie

Among patient with alcohol use disorders (AUD), cognitions (beliefs, thoughts, schemas) play an important role in alcohol abuse and in craving, defined as a strong and irresistible urge to consume a product. Various types of beliefs, said to be dysfunctional, were specifically identified among AUD patient as being able to favor a relapse. The aim of this research concerns the comorbidity (qualitative part of the research) and the dysfunctional beliefs relative to the craving (quantitative part of the research). The evolution of craving related beliefs are analyzed during a post-cure care. Ten French patients in post-cure care for AUD were received in clinical interview, and in structured interview (MINI). They also filled the French form of the Craving Beliefs Questionnaire at the two moments: At the beginning of post-cure care, then at the end. On the quantitative part, the results show that the irrational beliefs decrease among every patient. However, this evolution is not correlated with the number of post-cure care from which they benefit. A hypothesis is whether it is the global residential care in itself that influences the cognitions-beliefs.     

American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis

The American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma and Immunology Executive Committees formed the Omalizumab Joint Task Force with the purpose of reviewing the Genentech Xolair (omalizumab) clinical trials and postmarketing surveillance data on anaphylaxis and anaphylactoid reactions. Using the definition of anaphylaxis proposed at a 2005 multidisciplinary symposia, the Omalizumab Joint Task Force concluded that 35 patients had 41 episodes of anaphylaxis associated with Xolair (omalizumab) administration between June 1, 2003, and December 31, 2005. With 39,510 patients receiving Xolair (omalizumab) during the same period of time, this would correspond to an anaphylaxis-reporting rate of 0.09% of patients. Of those 36 events for which the time of reaction was known, 22 (61%) reactions occurred in the first 2 hours after one of the first 3 doses. Five (14%) of the events after the fourth or later doses occurred within 30 minutes. Considering the timing of these 36 events, an observation period of 2 hours for the first 3 injections and 30 minutes for subsequent injections would have captured 75% of the anaphylactic reactions. The OJTF report provides recommendations for physicians who prescribe Xolair (omalizumab) on (1) the suggested wait periods after administration and (2) patient education regarding anaphylaxis.